Tipifarnib
Tipifarnib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against CHURC1-FNTB protein.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
87 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | C92.0 | 4 | 9 | 2 | — | — | 14 | |
| Myelodysplastic syndromes | D009190 | D46 | 4 | 7 | 2 | — | — | 11 | |
| Leukemia | D007938 | C95 | 6 | 2 | 2 | — | — | 9 | |
| Megakaryoblastic leukemia acute | D007947 | C94.2 | 4 | 5 | 1 | — | — | 9 | |
| Monocytic leukemia acute | D007948 | 4 | 5 | 1 | — | — | 9 | ||
| Myelomonocytic leukemia acute | D015479 | C92.5 | 4 | 5 | 1 | — | — | 9 | |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 4 | 5 | 1 | — | — | 9 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 3 | 1 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 10 | — | — | — | 10 |
| Glioblastoma | D005909 | EFO_0000515 | 4 | 4 | — | — | — | 6 | |
| Myeloid leukemia | D007951 | C92 | 3 | 4 | — | — | — | 6 | |
| Gliosarcoma | D018316 | 3 | 2 | — | — | — | 4 | ||
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 3 | 3 | — | — | — | 4 | |
| Multiple myeloma | D009101 | C90.0 | 3 | 2 | — | — | — | 3 | |
| Basophilic leukemia acute | D015471 | C94.8 | 2 | 2 | — | — | — | 3 | |
| Eosinophilic leukemia acute | D015472 | 2 | 2 | — | — | — | 3 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 3 | — | — | — | 3 | |
| Medulloblastoma | D008527 | — | 3 | — | — | — | 3 |
Show 53 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TIPIFARNIB |
| INN | tipifarnib |
| Description | Tipifarnib is a quinolone that is 1-methylquinolin-2-one which carries a 3-chlorophenyl and an amino(4-chlorophenyl)(1-methyl-imidazol-5-yl)methyl groups at the 4 and 6 positions, respectively (the R-isomer). It has a role as an antineoplastic agent, an EC 2.5.1.58 (protein farnesyltransferase) inhibitor and an apoptosis inducer. It is a quinolone, a member of monochlorobenzenes, a member of imidazoles and a primary amino compound. |
| Classification | Small molecule |
| Drug class | farnesyl transferase inhibitor |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C |
Identifiers
| PDB | — |
| CAS-ID | 192185-72-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL289228 |
| ChEBI ID | — |
| PubChem CID | 159324 |
| DrugBank | DB04960 |
| UNII ID | MAT637500A (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,903 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
66 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more